At the 12th World Congress on Itch (WCI), held in Miami on November 5-7, 2023, InMed’s Senior VP, Clinical and Regulatory Affairs, Alexandra Mancini presented InMed’s Phase 2 clinical study results in a scientific poster. The poster “INM-755 cannabinol cream demonstrates anti-itch activity in patients with epidermolysis bullosa” described the Phase 2 clinical study of investigational drug INM-755 cannabinol (CBN) cream for the treatment of symptoms in patients with epidermolysis bullosa, a rare genetic skin condition.
View scientific poster here.
